Skip to main content
All lobbying filings

TIBER CREEK GROUP

Lobbying for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Pharmaceutical company.

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $80,000.00 income · posted Jul 18, 2025

Official filing document

 Bills named in this filing 3
  • S 1973
    Treat and Reduce Obesity Act of 2025
  • S 1041
    Affordable Prescriptions for Patients Act
  • S 1096
    Preserve Access to Affordable Generics and Biosimilars Act
 Lobbying activity 3
Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169). Issues related to the One Big Beautiful Bill Act (PL 119-21).

Health Issues

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Copyright/Patent/Trademark

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 Preserve Access to Affordable Generics and Biosimilars Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem